Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor
agonist intended for the treatment of cognitive disorders.